Artivion, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Artivion develops and sells medical devices and provides preservation services for cardiac and vascular surgery.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $77.2 million | $71.1 million; up 9% (11% excluding foreign exchange) |
| Gross margin | $50.7 million; 65.7% of revenue | $47.8 million; 67.3% |
| Operating income | $1.6 million | $1.4 million |
| Net loss / diluted loss per share | $3.4 million / $0.08 | $3.1 million / $0.08 |
| Operating cash flow | Use of $0.6 million | Use of $3.0 million |
| Cash and cash equivalents | $51.4 million at March 31 | $55.0 million at December 31, 2021 |
| Debt | $308.9 million net carrying amount; $316.9 million total loan balances before unamortized costs | — |
Cash decreased $3.6 million during the quarter. Investing activities used $2.7 million, including $2.2 million of capital expenditures; financing activities used $0.2 million. Working capital was $201.7 million, with a current ratio of approximately 6:1. Management said cash and expected operating cash flows should cover current operational liquidity needs for at least the next 12 months.
Material changes versus the prior-year quarter
- Revenue growth reflected aortic stent grafts (+26%), preservation services (+11%), and On-X products (+10%); surgical sealants declined 12% and other products declined 11%.
- Gross margin percentage fell from 67% to 66%, primarily due to product mix and higher material and labor costs.
- Research and development expense increased 31% to $10.1 million. General, administrative, and marketing expense was broadly flat at $39.0 million.
- Net loss increased modestly despite an improved pretax loss ($2.4 million versus $4.5 million), as the company recorded $1.0 million of income tax expense versus a $1.4 million tax benefit a year earlier. Lower foreign-currency-related other expense also benefited the comparison.
Outlook, risks, and unusual items
- No specific revenue or earnings guidance was provided. Management cited new products, new indications, global expansion, and business development as growth areas, while noting that results may fluctuate and quarterly results are not necessarily indicative of full-year performance.
- COVID-19-related hospital staffing constraints and procedure delays, workforce shortages, supply-chain disruption, and inflation could affect sales, costs, tissue processing, and clinical or regulatory timelines. The company had not yet experienced material supply-chain effects but said the risk was increasing.
- Foreign exchange reduced reported revenue growth; approximately 38% of cash was held outside the United States. The filing estimates that a further 10% adverse currency move on third-party foreign-currency balances could affect financial position or cash flows by about $8.0 million.
- Regulatory and execution risks include European certification transitions for BioGlue and PhotoFix, approvals and clinical timelines for pipeline products, and uncertainty over future hospital procedure volumes. The Ukraine war had not materially affected the business to date, but escalation could disrupt trade, supply, or costs.
- Debt includes a $100 million 4.25% convertible note due July 2025 and a secured term loan. The credit facility has springing maturity provisions tied to the notes; the company reported compliance with debt covenants. Management noted possible future financing needs if it pursues significant business development.
- Potential contingent payments include up to $100 million related to Ascyrus milestones and sales, a $5 million Endospan payment upon specified clinical milestones, and up to $9 million under the Baxter transaction. Ascyrus contingent consideration was valued at $47.6 million; a $1.8 million fair-value adjustment reduced expense in Q1.
- The company reported no pending legal matter it believed could have a material adverse effect based on current knowledge. Disclosure controls were assessed as effective; no material change in internal control over financial reporting was reported.
Most important facts for investors to verify
- Whether revenue growth—particularly in aortic stent grafts and preservation services—continues, and whether declining surgical sealant sales stabilize.
- Whether gross-margin pressure from mix, inflation, and labor costs persists, and whether higher R&D spending supports planned product approvals and launches.
- Cash generation, working-capital movements, and liquidity relative to debt service, clinical spending, and potential contingent payments.
- Progress and costs associated with BioGlue and PhotoFix certifications, BioGlue approval in China, and other clinical and regulatory milestones.
- Potential effects of hospital staffing and procedure delays, supply-chain and workforce constraints, currency movements, and geopolitical developments.